论文部分内容阅读
36例患者按(2:1)随机分为,对照组(n=12),罗格列酮组(n=24);对照组予改善生活方式;罗格列酮组予改善生活方式和罗格列酮4mg/日,结果经12周治疗后,对照组空腹及负荷后血糖及胰岛素与治疗前相比无明显统计学差异(P均>0.05);罗格列酮组治疗后空腹及负荷后血糖及胰岛素与治疗前及对照组治疗后相比明显下降(P均<0.05);治疗后对照组体重及BMI较治疗前下降(P<0.05);罗格列酮组体重及BMI与治疗前相比无明显变化(P>0.05);治疗前后对照组ISI较治疗前无明显变化;罗格列酮组ISI较治疗前明显升高(P<0.05),低血糖症状消失。结论对于以餐后低血糖反应为首发症状的T2DM患者,罗格列酮增加胰岛素敏感性,减轻餐后低血糖反应的发生。
Thirty-six patients were randomly divided into 2 groups: control group (n = 12), rosiglitazone group (n = 24); control group to improve their life style; rosiglitazone group to improve their lifestyle Glitazone 4mg / day, the results after 12 weeks of treatment, the control group fasting and post-load blood glucose and insulin compared with before treatment was no significant difference (P all> 0.05); rosiglitazone group after treatment fasting and load (P <0.05). After treatment, the body weight and BMI of the control group decreased compared with those before treatment (P <0.05); the body weight and BMI of the rosiglitazone group were significantly lower than those of the control group There was no significant difference between the two groups before and after treatment (P> 0.05). The ISI of the control group before and after treatment had no significant change compared with that before treatment. The ISI of rosiglitazone group was significantly higher than that before treatment (P <0.05), and the symptoms of hypoglycemia disappeared. Conclusions Rosiglitazone increases insulin sensitivity and reduces the incidence of postprandial hypoglycemia in T2DM patients with hypoglycemic response as the first symptom.